Prof. Zhiguo Luo 罗志国
Chief Physician, Professor
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of thoracic tumors, gastrointestinal tumors, and soft tissue tumors.
Dr. Luo is Deputy Director of the Department of Medical Oncology at Fudan University Shanghai Cancer Center. Dr. Luo earned a bachelor's degree from Jiangxi Medical College in 1993, a master's in oncology in 2001, and a doctorate in oncology from Peking Union Medical College Hospital in 2005. Since graduation, Dr. Luo has focused on clinical care and research for malignant tumors.
Professional roles
- Chair, Committee on Multiple Primary and Unknown Primary Tumors, Shanghai Anti-Cancer Association
- Vice Chair, Committee on Malignant Mesothelioma, China Anti-Cancer Association
- Vice Chair, Committee on Sarcoma, Shanghai Anti-Cancer Association
- Standing Committee Member, Sarcoma Expert Committee, Chinese Society of Clinical Oncology (CSCO)
Name order: in Chinese the family name comes first (Luo Zhiguo). Papers usually list the name as Zhiguo Luo or Luo Z.
Selected publications
54 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- Nat Commun, 2026 (senior author): Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial. PubMed 42103741
- MedComm (2020), 2025 (senior author): Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine. PubMed 40242159
- Clin Transl Med, 2025 (senior author): Fruquintinib as first-line or second-line treatment in unresectable or metastatic soft-tissue sarcoma: A prospective, single-arm phase II study. PubMed 40235094
- Cancer Med, 2023 (senior author): Clinical features and prognosis of patients with metastatic ocular and orbital melanoma: A bi-institutional study. PubMed 37409486
- Cancer Res Treat, 2023 (senior author): Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single- Center Study. PubMed 36915248
- Front Oncol, 2023 (senior author): Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring ALK-IGFBP5 fusion. PubMed 37035208
- Clin Cancer Res, 2022 (senior author): Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study. PubMed 36239473
- Invest New Drugs, 2022 (senior author): Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data. PubMed 34731354
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion